| Summary: | Inflammatory bowel diseases (IBDs) involving Crohn’s disease (CD) and ulcerative colitis (UC) are gastrointestinal (GI) disorders in which abdominal pain, discomfort, and diarrhea are the major symptoms. The immune system plays an important role in the pathogenesis of IBD and, as indicated by several clinical studies, both innate and adaptative immune response has the faculty to induce gut inflammation in UC patients. An inappropriate mucosal immune response to normal intestinal constituents is a main feature of UC, thus leading to an imbalance in local pro- and anti-inflammatory species. <i>Ulva pertusa</i>, a marine green alga, is known for its important biological properties, which could represent a source of beneficial effects in various human pathologies. We have already demonstrated the anti-inflammatory, antioxidant, and antiapoptotic effects of an <i>Ulva pertusa</i> extract in a murine model of colitis. In this study, we aimed to examine thoroughly <i>Ulva pertusa</i> immunomodulatory and pain-relieving properties. Colitis was induced by using the DNBS model (4 mg in 100 μL of 50% ethanol), whereas <i>Ulva pertusa</i> was administered daily at the dosage of 50 and 100 mg/kg by oral gavage. <i>Ulva pertusa</i> treatments have been shown to relieve abdominal pain while modulating innate and adaptative immune-inflammatory responses. This powerful immunomodulatory activity was specifically linked with TLR4 and NLRP3 inflammasome modulation. In conclusion, our data suggest <i>Ulva pertusa</i> as a valid approach to counteract immune dysregulation and abdominal discomfort in IBD.
|
|---|